List of Excipients in Branded Drug YEZTUGO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Gilead Sciences Inc	YEZTUGO	lenacapavir sodium	61958-3401	CELLULOSE, MICROCRYSTALLINE	2028-06-18
Gilead Sciences Inc	YEZTUGO	lenacapavir sodium	61958-3401	COPOVIDONE K25-31	2028-06-18
Gilead Sciences Inc	YEZTUGO	lenacapavir sodium	61958-3401	CROSCARMELLOSE SODIUM	2028-06-18
Gilead Sciences Inc	YEZTUGO	lenacapavir sodium	61958-3401	MAGNESIUM STEARATE	2028-06-18
Gilead Sciences Inc	YEZTUGO	lenacapavir sodium	61958-3401	MANNITOL	2028-06-18

YEZTUGO Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

Yeztugo, Gilead Sciences’ twice-yearly injectable lenacapavir for HIV pre-exposure prophylaxis, creates commercial opportunities in sterile excipients, depot-injection manufacturing, primary packaging, analytical testing, and generic-entry risk management. Its value proposition depends on maintaining lenacapavir’s long subcutaneous residence time while controlling injection volume, local tolerability, particulate risk, and six-month product stability.

The largest opportunities are unlikely to come from simple substitution of common tablet excipients. They are concentrated in high-quality sterile excipients, container-closure systems, injectable manufacturing capacity, and differentiated long-acting delivery technologies.

What is Yeztugo and how is it administered?

Yeztugo is a lenacapavir-based HIV prevention product approved by the U.S. Food and Drug Administration in June 2025 for adults and adolescents weighing at least 35 kg who are HIV-negative and at substantial risk of acquiring HIV [1].

Attribute	Yeztugo
Active ingredient	Lenacapavir
Therapeutic use	HIV pre-exposure prophylaxis
FDA pathway	New drug application
Administration	Subcutaneous injection every six months after oral initiation
Commercial sponsor	Gilead Sciences
Patient population	Adults and adolescents at least 35 kg
Product type	Small-molecule long-acting injectable plus oral loading regimen
Biosimilar classification	Not applicable
Main competitive advantage	Twice-yearly dosing

The product uses an oral initiation regimen followed by subcutaneous administration. The injection is supplied in single-dose vials and is administered in two injection sites per dosing visit, according to the FDA prescribing information [2].

The delivery schedule reduces dependence on daily adherence, which is a central commercial distinction from oral pre-exposure prophylaxis products such as Truvada and Descovy.

What excipients are used in Yeztugo?

Yeztugo has two distinct excipient systems: one for the injectable formulation and another for the oral tablets. The injectable formulation has the greater strategic importance because it must remain stable for long-term storage, support subcutaneous administration, and avoid excessive injection-site reactions.

Injectable formulation

The FDA-approved injection uses a relatively limited excipient platform centered on:

• Water for injection
• Sodium chloride
• Polysorbate 20

The formulation is designed for parenteral use and must control sterility, osmolality, colloidal stability, visible and subvisible particles, and adsorption to the vial and delivery components [2].

Polysorbate 20 is commercially important because surfactants can degrade through oxidation and hydrolysis. Degradation products may increase particulate formation or affect protein products, although lenacapavir is a small molecule. For a long-acting suspension or solution intended to remain stable over extended storage, the sponsor must control surfactant purity, peroxide burden, trace metals, and lot-to-lot variability.

Sodium chloride provides tonicity adjustment. Water for injection is the primary solvent and must meet compendial and microbiological specifications appropriate for sterile drug manufacturing.

Oral tablet formulation

The oral loading dose uses conventional solid-dose excipients. These typically support:

• Direct compression or granulation
• Tablet disintegration
• Content uniformity
• Film coating
• Mechanical strength
• Stability during distribution

The tablet excipient system has lower technical differentiation than the injection. Its commercial value is tied to reliable high-volume supply, low extractables and leachables risk, and compatibility with Gilead’s validated manufacturing process.

The exact approved inactive-ingredient composition should be taken from the current FDA prescribing information and product labeling because excipient composition can differ between product presentations and markets [2,3].

How does the Yeztugo excipient strategy support long-acting delivery?

The formulation strategy supports a six-month dosing interval through the physicochemical properties of lenacapavir rather than through a complex polymeric implant.

Lenacapavir has high potency and a long pharmacokinetic half-life. The product therefore does not require a high daily dose or a large-volume depot system. This creates several formulation advantages:

1. The dose can be delivered subcutaneously rather than intravenously.
2. The formulation can use a relatively simple excipient system.
3. The product avoids an implant procedure.
4. The dosing schedule supports administration in clinics, pharmacies, or public-health settings.
5. The absence of a biodegradable polymer may reduce certain manufacturing and degradation risks.

The principal formulation challenge is local tolerability. Two subcutaneous injections at each six-month visit create a tradeoff between dose concentration and injection volume. Increasing concentration can reduce volume but may increase viscosity, precipitation risk, or injection-site discomfort.

The critical quality attributes include:

Quality attribute	Commercial and regulatory relevance
Assay and purity	Controls dose delivery and degradation
Particle size or physical state	Affects dissolution and absorption
pH	Affects stability and tissue tolerability
Osmolality	Affects injection-site tolerability
Subvisible particles	Important for injectable safety
Surfactant degradation	Can affect stability and particulates
Container adsorption	Can reduce delivered dose
Sterility and endotoxin	Required for parenteral approval
Vial integrity	Protects the six-month product shelf life
Injection force	Affects usability and administration setting

What commercial opportunities exist for Yeztugo excipients?

The highest-value opportunities are in qualified suppliers with sterile manufacturing and regulatory support.

Sterile excipient supply

Yeztugo creates demand for pharmaceutical-grade polysorbate 20, sodium chloride, and water for injection. A supplier must provide more than compendial conformity. Gilead’s qualification process is likely to examine:

• Oxidative impurity profile
• Peroxide content
• Trace metals
• Bioburden and endotoxin control
• Batch consistency
• Manufacturing-site controls
• Change-notification procedures
• Global regulatory documentation

Sterile excipient suppliers with redundant manufacturing sites and strong change-control systems have an advantage. A supplier failure could affect the entire product because the formulation uses a narrow excipient platform.

Primary packaging and delivery components

Commercial opportunities extend beyond excipients to:

• Type I glass vials
• Elastomeric stoppers
• Aluminum seals
• Prefilled syringe components, if later presentations are developed
• Needles and safety devices
• Secondary packaging for two-injection dosing

Container-closure compatibility is particularly important for a product with a long shelf life and low dosing frequency. Extractables and leachables studies must cover the vial, stopper, seal, syringe, needle, and administration accessories.

Contract manufacturing

Yeztugo may increase demand for contract development and manufacturing organizations with:

• Sterile fill-finish capacity
• Aseptic processing
• Low-volume parenteral handling
• Long-term stability programs
• High-containment or potent-compound capabilities
• Global regulatory inspection experience

The oral tablet component creates a separate opportunity for contract solid-dose manufacturing and packaging. However, sterile fill-finish capacity is likely to command greater strategic value.

Analytical testing

Testing providers can capture work in:

• Surfactant degradation
• Particulate characterization
• Container-closure integrity
• Sterility and endotoxin
• Lenacapavir impurities
• Extractables and leachables
• In-use stability
• Photostability
• Freeze-thaw and shipping studies

Six-month dosing increases the commercial cost of product failure. Analytical methods must therefore support long-term stability claims and product-release consistency.

What formulation patents protect Yeztugo?

Lenacapavir’s core patent estate is likely to include composition-of-matter, pharmaceutical composition, crystalline form, formulation, manufacturing, and method-of-use claims.

The most commercially important claim categories are:

Composition-of-matter claims

These protect lenacapavir and related chemical structures. Composition claims generally create the strongest barrier to generic competition because a competing manufacturer cannot commercialize the same active ingredient until the relevant claims expire or are successfully challenged.

Long-acting formulation claims

These may cover:

• Injectable lenacapavir compositions
• Concentration ranges
• pH and osmolality ranges
• Subcutaneous administration
• Dosing intervals
• Specific excipient combinations
• Physical forms or particle characteristics

A formulation claim can remain commercially relevant even after a basic active-ingredient patent expires if a generic product must use the same long-acting delivery profile to compete effectively.

Method-of-use claims

Yeztugo’s PrEP indication may be protected by claims directed to:

• Preventing HIV acquisition
• Administration to HIV-negative individuals
• Six-month dosing
• Specific loading and maintenance regimens
• Use in defined patient populations

Method-of-use patents are relevant to Paragraph IV litigation and skinny-label strategies. A generic manufacturer may attempt to omit a patented indication while retaining approval for an unprotected use.

Manufacturing patents

Manufacturing claims may protect:

• Lenacapavir synthesis routes
• Purification
• Crystallization
• Particle engineering
• Sterile formulation processing
• Vial filling and stability methods

These claims can raise the cost of independent development even when they do not block all alternative manufacturing routes.

When does Yeztugo lose exclusivity?

Yeztugo has multiple exclusivity layers rather than one single expiration date.

Exclusivity layer	Relevance
New chemical entity exclusivity	May delay certain ANDA approvals
Clinical investigation exclusivity	Can protect the approved indication for a defined period
Pediatric exclusivity	May add six months if granted
Composition patents	Primary barrier to active-ingredient copying
Formulation patents	Can delay equivalent long-acting products
Method-of-use patents	Can limit labeled PrEP competition
Manufacturing patents	Can increase development cost
Regulatory exclusivity outside the U.S.	Varies by jurisdiction

Gilead has publicly described a lenacapavir patent position extending into the late 2030s for key uses of the molecule [4]. The effective loss-of-exclusivity date for Yeztugo will depend on the interaction between Orange Book-listed patents, patent-term adjustment, patent-term extension, pediatric exclusivity, and any settlement agreements.

An exact commercial entry date cannot be inferred from the active-ingredient patent alone. Long-acting formulation and method-of-use claims may determine whether an approved generic can launch with the same dosing schedule.

What is the Orange Book status of Yeztugo?

Yeztugo is an FDA-approved small-molecule drug and is eligible for Orange Book listing. Orange Book records may identify patents covering the drug substance, drug product, or approved method of use [5].

The relevant legal questions are:

• Which patents are listed against the Yeztugo NDA?
• Do listed patents cover the injection, tablets, or both?
• Are any patents directed specifically to the six-month PrEP regimen?
• Has Gilead received patent-term extension?
• Have generic applicants submitted Paragraph IV certifications?
• Has Gilead filed infringement litigation within the statutory window?

The Orange Book should be reviewed alongside FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations and the relevant patent litigation docket. Patent listings can change after approval, and later-listed patents may affect future generic applications.

Which companies could challenge Yeztugo?

Potential challengers include large generic manufacturers with:

• Injectable manufacturing capability
• Experience with complex generics
• HIV antiviral development programs
• Long-acting formulation expertise
• Patent litigation resources

The likely competitive field includes major generic companies such as Viatris, Teva Pharmaceutical Industries, Sandoz, Lupin, Sun Pharma, Cipla, and Dr. Reddy’s Laboratories. Their ability to challenge Yeztugo will depend on access to lenacapavir, development of an equivalent injectable presentation, and the scope of Gilead’s formulation and method-of-use patents.

A generic oral lenacapavir product would not necessarily compete directly with Yeztugo’s principal value proposition. The commercial challenge is a therapeutically equivalent six-month injectable product.

What Paragraph IV risks exist for Yeztugo?

A Paragraph IV applicant could argue that listed patents are:

• Invalid
• Unenforceable
• Not infringed
• Improperly listed
• Inapplicable to the proposed product

The strongest potential challenge would target patents with narrow formulation or dosing claims. Composition-of-matter claims generally present a more substantial barrier if they remain valid and enforceable.

A generic applicant could also pursue a non-infringing formulation using different:

• Surfactants
• Tonicity agents
• Concentrations
• Particle characteristics
• Container materials
• Administration schedules

That strategy would increase development and clinical-bridging requirements. It could also produce a product that is legally non-infringing but commercially less attractive if it requires more injections or has inferior tolerability.

How does Yeztugo compare with competing HIV PrEP products?

Product	Active ingredient	Dosing	Delivery	Main commercial limitation
Yeztugo	Lenacapavir	Every six months	Subcutaneous injection	Injection-site reactions, clinic access, high manufacturing complexity
Descovy	Emtricitabine/tenofovir alafenamide	Daily	Oral tablet	Daily adherence; indication limitations in some populations
Truvada and generics	Emtricitabine/tenofovir disoproxil fumarate	Daily or event-driven in some settings	Oral tablet	Daily adherence and renal/bone considerations
Apretude	Cabotegravir	Every two months	Intramuscular injection	More frequent visits and injections
Lenacapavir treatment products	Lenacapavir	Long-acting treatment component	Subcutaneous injection plus oral therapy	Treatment use differs from PrEP

Yeztugo’s main competitive advantage is dosing frequency. Its main commercial barriers are injection logistics, affordability, HIV testing requirements before administration, and the need to maintain follow-up over a six-month cycle.

What FDA and access issues affect Yeztugo commercialization?

Yeztugo administration requires confirmation that the patient is HIV-negative before initiation and before subsequent injections. Missed injections create a regulatory and clinical-management issue because declining drug concentrations may expose patients to subtherapeutic levels.

Commercial uptake will depend on:

• Reimbursement for drug and administration
• Pharmacy and clinic distribution
• HIV testing infrastructure
• Cold-chain and inventory requirements
• Patient willingness to receive injections
• Public-health procurement
• Access in high-incidence regions
• Training for healthcare professionals

The product may be especially valuable in public-health programs serving patients for whom daily oral adherence is difficult. Commercial expansion outside the United States will depend on local regulatory approvals, procurement systems, and country-specific patent enforcement.

How strong is the Yeztugo patent estate?

The estate is commercially strong if Gilead has overlapping protection across the active ingredient, injectable formulation, dosing regimen, and manufacturing process.

Its strongest features are likely to be:

• A differentiated long-acting molecule
• A six-month PrEP regimen
• A complex injectable product
• High technical barriers to bioequivalence
• Limited substitutability between oral and injectable products
• Manufacturing and analytical requirements that exceed those of standard tablets

The principal vulnerability is that a generic may attempt to design around narrow excipient or dosing claims. The practical protection of the estate will depend on claim breadth, patent validity, Orange Book listing quality, and whether a challenger can establish equivalence without copying the protected formulation.

What licensing and partnership opportunities exist?

The most attractive partnerships are likely to involve delivery and access rather than basic excipient licensing.

Potential structures include:

• Regional licenses for manufacturing or distribution
• Public-health procurement agreements
• Partnerships with injectable contract manufacturers
• Technology licenses for alternative depot systems
• Agreements with diagnostic providers for HIV testing integration
• Co-development of lower-cost presentations
• Licensing for pediatric or adolescent delivery systems
• Local fill-finish arrangements in high-incidence countries

Excipient companies may not obtain a direct product license. Their leverage is more likely to come from dual-source qualification, proprietary low-peroxide surfactant grades, sterile supply, and validated container-closure systems.

Key Takeaways

• Yeztugo is a twice-yearly subcutaneous lenacapavir PrEP product approved by FDA in 2025.
• Its commercial differentiation comes from dosing frequency, not a novel excipient platform.
• The injection relies on a comparatively simple sterile excipient system, increasing the importance of supplier quality and consistency.
• Polysorbate 20, sodium chloride, water for injection, sterile fill-finish, and packaging components are the clearest near-term supply opportunities.
• The strongest generic barriers are likely to be lenacapavir composition claims, long-acting formulation claims, dosing-regimen claims, and injectable manufacturing complexity.
• Yeztugo is a small-molecule product, so generic competition, not biosimilar competition, is the relevant pathway.
• Orange Book listings, Paragraph IV certifications, and method-of-use patents will determine the timing of U.S. generic risk.
• Commercial adoption will depend on reimbursement, HIV testing, injection capacity, and public-health procurement as much as on formulation performance.

FAQs

Can excipient suppliers replace polysorbate 20 in Yeztugo?

A substitute could be technically feasible, but it would require formulation redevelopment, stability data, compatibility testing, and regulatory review. A substitution would not automatically be interchangeable with the approved product.

Is Yeztugo difficult to manufacture as a generic?

Yes. A generic manufacturer must address sterile processing, long-term stability, injection-site performance, device and vial compatibility, and complex bioequivalence requirements. The barriers are higher than for a conventional oral tablet.

Does Yeztugo have biosimilar competition?

No. Lenacapavir is a chemically synthesized small molecule. The relevant competitors are ANDA-based generics or other independently developed injectable products.

Could a different excipient combination avoid Yeztugo patents?

Potentially, if the relevant claims are limited to specific excipients or concentration ranges. A design-around would still need to demonstrate pharmaceutical equivalence, bioequivalence, stability, sterility, and clinical suitability.

What is the most attractive commercial segment around Yeztugo?

Sterile injectable supply and manufacturing have the strongest strategic value. High-quality polysorbate 20, water for injection, vial systems, analytical testing, and aseptic fill-finish capacity are more defensible opportunities than standard oral-tablet excipients.

References

1. U.S. Food and Drug Administration. (2025, June 18). FDA approves first injectable option for HIV pre-exposure prophylaxis. https://www.fda.gov
2. U.S. Food and Drug Administration. (2025). Yeztugo (lenacapavir) prescribing information. https://www.accessdata.fda.gov
3. DailyMed. (2025). Yeztugo- lenacapavir sodium tablet and injection. National Library of Medicine. https://dailymed.nlm.nih.gov
4. Gilead Sciences, Inc. (2025). Annual report and corporate product information for lenacapavir. https://www.gilead.com
5. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/apps/obtb/outer.html